Lilly holds a 60.9% U.S. obesity drug market share, but faces a Michigan AG probe into insulin pricing and a Novo Nordisk lawsuit over "deceptive" GLP-1 ads. Watch for rulings on these legal challenges and further developments in retatrutide's compassionate use access.